Search results
Results From The WOW.Com Content Network
Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including Cetus Corporation which was founded in 1971.
Autogene cevumeran is an investigational mRNA vaccine being developed jointly by BioNTech and Genentech as an adjuvant therapy in cancer treatment to prevent cancer recurrence following surgery. [1][2][3] Autogene cevumeran is a type of individualised neoantigen-specific immunotherapy containing multiple different mRNA species that together ...
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann ...
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers -- -- Early ...
Product pipeline. A product pipeline is a series of products, either in a state of development, preparation, or production, [1] developed and sold by a company, and ideally in different stages of their life cycle. At any point in a company's life, the goal is to have some products in the growth stage, which is the key stage for establishing a ...
Roche. F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [13] and Christoph Huber, [14] with a seed investment of €150 million from MIG Capital, a Munich-based venture capital firm, and AT Impf, an investment vehicle under control of the single family office of German billionaire twin brothers, Andreas and Thomas Strüngmann.
Casper Hoogenraad is a Dutch Cell Biologist who specializes in molecular neuroscience. The focus of his research is the basic molecular and cellular mechanisms that regulate the development and function of the brain. As of January 2020, he serves as Vice President of Neuroscience at Genentech Research and Early Development.